Altimmune's Groundbreaking Phase 2 Trial for AUD
Altimmune, Inc. is making strides in the field of biopharmaceuticals, particularly targeting Alcohol Use Disorder (AUD) through its innovative drug pemvidutide. This investigational agent is a GLP-1/glucagon dual receptor agonist aimed at treating various metabolic conditions, including metabolic dysfunction-associated steatohepatitis (MASH), obesity, AUD, and alcohol liver disease (ALD). Recently, Altimmune announced the enrollment of the first participant in its RECLAIM Phase 2 trial, showcasing their commitment to addressing a critical health challenge.
The RECLAIM Trial: Structure and Goals
The RECLAIM trial is designed as a randomized, placebo-controlled study. It involves approximately 100 participants across around 15 sites throughout the United States, with Dr. Henry Kranzler leading the research as the Principal Investigator. Participants will be randomly assigned to receive either 2.4 mg of pemvidutide or a placebo weekly for 24 weeks. The primary goal is assessing the change in alcohol consumption, specifically looking at heavy drinking days per week. Secondary objectives will measure the reduction in the World Health Organization (WHO) risk drinking levels.
The Urgent Need for Effective AUD Treatments
A staggering 28 million people in the United States struggle with AUD, yet effective treatments remain scarce. Research indicates that less than 10% of those affected receive adequate treatment, and merely 2% take the medications currently approved for AUD. These existing drugs have limitations in their effectiveness, highlighting the dire need for a new approach. Dr. Kranzler points out that ensuring more patients receive the help they need is critical in closing what is recognized as a significant treatment gap.
Potential of GLP-1 Agents in Reducing Alcohol Cravings
Scott Harris, M.D., the Chief Medical Officer of Altimmune, emphasizes that GLP-1 agents are showing promising data in reducing alcohol cravings in addition to managing food consumption. In studies on a preclinical model, pemvidutide demonstrated a more than 80% reduction in alcohol preference, suggesting its potential efficacy for individuals battling AUD. This correlation with obesity risks provides even further validity, as excess alcohol consumption can exacerbate many metabolic conditions.
Altimmune’s Impact on Treatment Landscapes
As a late clinical-stage biopharmaceutical company, Altimmune aims to innovate how AUD and related conditions are treated. Pemvidutide stands at the forefront of the company’s initiatives, representing hope for thousands facing the challenges of AUD and its related health risks.
Key Takeaways from the RECLAIM Trial
Through the RECLAIM trial, Altimmune aims to uncover critical data that could pave the way for pemvidutide's approval, offering new hope to those impacted by AUD. The potential for a new standard of care not only for AUD but also for complications arising from associated conditions is significant.
About Altimmune
Founded with a mission to develop groundbreaking peptide-based therapeutics, Altimmune focuses on liver and cardiometabolic diseases. Their lead program, pemvidutide, embodies a multi-faceted approach towards treating MASH, obesity, AUD, and ALD. This dedication highlights Altimmune’s commitment to improving patient outcomes and transforming existing treatment protocols.
Frequently Asked Questions
What is the RECLAIM Phase 2 trial?
The RECLAIM Phase 2 trial evaluates the efficacy and safety of pemvidutide in treating Alcohol Use Disorder (AUD).
Who is the Principal Investigator for this trial?
Dr. Henry Kranzler, from the University of Pennsylvania Perelman School of Medicine, is leading the trial.
What are the main goals of the trial?
The trial aims to assess changes in alcohol consumption and measure key secondary health indicators after treatment.
How does pemvidutide work?
Pemvidutide acts as a GLP-1/glucagon dual receptor agonist, targeting metabolic functions to help reduce cravings and alcohol consumption.
What does the enrollment process for the trial involve?
Approximately 100 subjects will be randomized to receive either pemvidutide or a placebo, following a structured weekly dosing for 24 weeks.
